ANN ARBOR, Mich., Jan. 6 /PRNewswire/ -- Ann Arbor-based Genetics Squared has announced the appointments of Dr. Peter Lenehan and Dr. David Fry to the positions of chief medical officer and chief science officer, respectively. Each brings decades of research and development experience to the company and have previously worked together on multiple targeted oncology drug development teams at Pfizer and previously Parke-Davis/Warner-Lambert.
"Genetics Squared is very excited to add these two exceptional individuals to its management team," said president and CEO John Freshley. "They have successfully worked together in the past and that is an important additional benefit to the company."
Peter Lenehan, M.D., Ph.D.
As chief medical officer, Dr. Lenehan will be responsible for the acquisition and clinical development of "promising but struggling" clinical oncology compounds using Genetics Squared's evolutionary drug development(TM) technology. Most recently, Dr. Lenehan was director of clinical oncology at Pfizer, where he led the early clinical development of many cancer therapies for solid tumors.
Dr. Lenehan brings a combined 24 years of basic cancer research and clinical oncology experience. Having conducted laboratory-based research in human leukemia at the Sloan-Kettering Institute for Cancer Research in NYC, he received a Ph.D. in 1982 and an M.D. in 1984 from SUNY Downstate Medical Center, Brooklyn, NY.
After completing his medical training at Jefferson Medical College in Philadelphia and a hematology-oncology fellowship at the University of Maryland Cancer Center in Baltimore, he joined the faculty of the University of Maryland School of Medicine. There, in the Laboratory of Developmental Therapeutics at the Cancer Center, he pursued basic research on the mechanisms of multi-drug resistance in human leukemia and clinical studies of novel anticancer compounds.
"Genetics Squared is thrilled that Dr. Lenehan has chosen to lead its clinical development efforts," said Freshley. "Peter brings a wealth of industry and academic research experience that will immediately impact Genetics Squared's ability to successfully rescue promising cancer therapies that have yet to find the ideal patient population."
David Fry, Ph.D.
Dr. Fry is already an active member of Genetics Squared's Scientific Advisory Board. As chief science officer, Dr. Fry will lead the discovery of appropriate biomarkers and combinations of biomarkers to identify the optimal patient population for drugs in-licensed by the company for redevelopment.
Over the past 18 months, Dr. Fry has been a lecturer and consultant on drug discovery and targeted therapy. Prior to his consulting activities, Dr. Fry worked for 21 years in the pharmaceutical industry where he led oncology drug discovery efforts at Pfizer's Ann Arbor laboratories as a senior research fellow. During his tenure at Pfizer, his professional activities focused on target oriented drug discovery, biochemical mechanisms of anticancer agents, the role of signal transduction pathways in growth regulation, and oncogenesis and cell cycle regulation and its therapeutic application.
He has published more than 120 scientific manuscripts on drug discovery, biochemistry and pharmacology of anticancer agents and has co-authored 13 issued or pending patents. While at Parke-Davis, Dr. Fry was responsible for the discovery of several targeted cancer therapies that have advanced into clinical development.
"Genetics Squared has enjoyed its existing consulting and advisory relationship with Dr. Fry and is excited that he has agreed to expand his commitment to Genetics Squared," said Freshley. "With his background and experience, Dave is the ideal person to fill this critical role in the company."
About Genetics Squared
Founded in 2002, Genetics Squared is an emerging biotechnology company focused on delivering the promise of personalized medicine. Using its patented evolutionary drug development(TM) technology and methods, Genetics Squared is able to "rescue" promising, but struggling compounds from clinical and market failure. The company's novel analytical approach discovers profiles of therapeutic responders and non-responders or those most likely to experience serious adverse events based on medical history, patient demographics, genetic and protein biomarkers. This allows the company and its service clients to target these promising therapies at the patients most likely to benefit. For more information, please visit http://www.genetics2.com/ .